Switching from premixed human insulin to premixed insulin lispro: A prospective study comparing the effects on glucose control and quality of life

Internal Medicine

Volumn 46, Issue 18, 2007, Pages 1513-1517

  Yamada, Satoru ^a   Watanabe, Mari ^b   Kitaoka, Akira ^b   Shiono, Kaoru ^b   Atsuda, Koichiro ^b   Tsukamoto, Youko ^a   Kawana, Yukiko ^a   Irie, Junichiro ^a  

^a KITASATO INSTITUTE HOSPITAL   (Japan)

^b KITASATO UNIVERSITY   (Japan)

Author keywords

Glycemic control; Insulin analogue; Quality of life

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN DERIVATIVE; INSULIN LISPRO;

ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN HYPOGLYCEMIA; INSULIN TREATMENT; JAPAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT SATISFACTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

AGED; BLOOD GLUCOSE; CHEMISTRY, PHARMACEUTICAL; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE;

EID: 34948843029     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.46.0236     Document Type: Article

References (15)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977-986, 1993.
2. U.K. Prospective Diabetes Study (UKPDS) group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33). Lancet 352: 837-853, 1998.
3. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28: 103-117, 1995.
4. DECODE Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria. Lancet 354: 617-621, 1999.
5. Nakagami T, DECODA Study Group. Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia 47: 385-394, 2004.
6. Tominaga M, Eguchi H, Nakata H, et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: the Funagata Diabetes Study. Diabetes Care 22: 920-924, 1999.
7. Hirsch IB, Bergenstal RM, Parkin CG, et al. A real-world approach to insulin therapy in primary care practice. Clinical Diabetes 23: 78-86, 2005.
8. Yamada S, Tamada T, Watanabe M, et al. Comparison of biphasic insulin aspart 30/70 and premixed human insulin 30/70: Glycemic control and quality of life in insulin-naïve type 2 diabetic patients. Clinical Practice 26: 58-64, 2007.
9. Ishii H, Yamamoto T, Ohashi Y. Development of insulin therapy related quality of life measure (ITR-QOL). J Jpn Diabetes Soc 44: 9-15, 2001 (in Japanese).
10. Bradley C. Diabetes treatment satisfaction questionnaire (DTSQ). In: Handbook of Psychology and Diabetes. Bradley C, Ed. Harwood Academic Publishers, 1994. Chur. P111-132.
11. Roach P, Arora V, Campaigne BN, et al. Humalog Mix50 before carbohydrate-rich meals in type 2 diabetes mellitus. Diabetes Obes Metab 5: 311-316, 2003.
12. Iwamoto Y, Kawamori R, Kadowaki T, Akanuma Y, Beattie SD, Malone JK. Clinical study of insulin lispro mixture-25 and mixture 50 administered twice daily in insulin-requiring patients with type 1 and type 2 diabetes mellitus. Rinsho Iyaku 18: 395-409, 2002 (in Japanese).
13. Ross SA, Zinman B, Campos RV, Strack T, Canadian Lispro Study Group. A comparative study of insulin lispro and human regular insulin in patients with type 2 diabetes mellitus and secondary failure of oral hypoglycemic agents. Clin Invest Med 24: 292-298, 2001.
14. Roach P, Yue L, Arora V, The Humalog Mix25 Study Group. Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Diabetes Care 22: 1258-1261, 1999.
15. Boehm BO, Home PD, Behrendt C, Kampt NM, Lidholmt A. Premixed insulin aspart 30/70 twice daily: a randomized trial in type 1 and type 2 diabetic patients. Diabet Med 19: 393-399, 2002.